Provectus Biopharmaceuticals, Inc. (PVCT)
USD 0.1
(-3.01%)
USD 0.1
(-3.01%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.44 Million USD | -28.88% |
| 2022 | 2.03 Million USD | -42.01% |
| 2021 | 3.51 Million USD | 496.29% |
| 2020 | 589.2 Thousand USD | -60.11% |
| 2019 | 1.47 Million USD | -25.72% |
| 2018 | 1.98 Million USD | -42.14% |
| 2017 | 3.43 Million USD | -38.76% |
| 2016 | 5.61 Million USD | -72.55% |
| 2015 | 20.43 Million USD | -21.94% |
| 2014 | 26.18 Million USD | 30.87% |
| 2013 | 20 Million USD | 222.48% |
| 2012 | 6.2 Million USD | -53.52% |
| 2011 | 13.34 Million USD | -7.31% |
| 2010 | 14.4 Million USD | 40.74% |
| 2009 | 10.23 Million USD | -2.7% |
| 2008 | 10.51 Million USD | -33.06% |
| 2007 | 15.71 Million USD | -3.76% |
| 2006 | 16.32 Million USD | -5.74% |
| 2005 | 17.31 Million USD | 54.69% |
| 2004 | 11.19 Million USD | -43.53% |
| 2003 | 19.82 Million USD | -6.28% |
| 2002 | 21.15 Million USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 856.42 Thousand USD | -20.63% |
| 2024 Q1 | 1.07 Million USD | -25.53% |
| 2023 FY | 1.44 Million USD | -28.88% |
| 2023 Q3 | 1.69 Million USD | 0.21% |
| 2023 Q2 | 1.68 Million USD | -1.96% |
| 2023 Q1 | 1.72 Million USD | -15.56% |
| 2023 Q4 | 1.44 Million USD | -14.27% |
| 2022 Q2 | 2.44 Million USD | -11.33% |
| 2022 FY | 2.03 Million USD | -42.01% |
| 2022 Q1 | 2.75 Million USD | -21.56% |
| 2022 Q4 | 2.03 Million USD | -0.64% |
| 2022 Q3 | 2.05 Million USD | -16.08% |
| 2021 Q1 | 771.42 Thousand USD | 30.93% |
| 2021 Q3 | 600.33 Thousand USD | 28.74% |
| 2021 FY | 3.51 Million USD | 496.29% |
| 2021 Q2 | 466.29 Thousand USD | -39.55% |
| 2021 Q4 | 3.51 Million USD | 485.23% |
| 2020 Q1 | 819.96 Thousand USD | -44.48% |
| 2020 FY | 589.2 Thousand USD | -60.11% |
| 2020 Q2 | 1.83 Million USD | 124.23% |
| 2020 Q3 | 1.34 Million USD | -26.86% |
| 2020 Q4 | 589.2 Thousand USD | -56.19% |
| 2019 Q4 | 1.47 Million USD | -5.57% |
| 2019 Q3 | 1.56 Million USD | -42.47% |
| 2019 FY | 1.47 Million USD | -25.72% |
| 2019 Q1 | 3.69 Million USD | 85.71% |
| 2019 Q2 | 2.71 Million USD | -26.38% |
| 2018 Q3 | 2.42 Million USD | -31.3% |
| 2018 FY | 1.98 Million USD | -42.14% |
| 2018 Q4 | 1.98 Million USD | -17.92% |
| 2018 Q1 | 3.05 Million USD | -11.02% |
| 2018 Q2 | 3.52 Million USD | 15.32% |
| 2017 Q2 | 4.92 Million USD | 9.29% |
| 2017 Q1 | 4.51 Million USD | -19.62% |
| 2017 Q3 | 3.85 Million USD | -21.85% |
| 2017 FY | 3.43 Million USD | -38.76% |
| 2017 Q4 | 3.43 Million USD | -10.8% |
| 2016 FY | 5.61 Million USD | -72.55% |
| 2016 Q4 | 5.61 Million USD | -47.49% |
| 2016 Q3 | 10.68 Million USD | -1.32% |
| 2016 Q1 | 16.01 Million USD | -21.63% |
| 2016 Q2 | 10.82 Million USD | -32.4% |
| 2015 Q2 | 31.24 Million USD | 37.2% |
| 2015 FY | 20.43 Million USD | -21.94% |
| 2015 Q4 | 20.43 Million USD | -23.17% |
| 2015 Q3 | 26.6 Million USD | -14.85% |
| 2015 Q1 | 22.77 Million USD | -13.03% |
| 2014 Q2 | 22.09 Million USD | 6.29% |
| 2014 FY | 26.18 Million USD | 30.87% |
| 2014 Q1 | 20.79 Million USD | 3.91% |
| 2014 Q4 | 26.18 Million USD | 20.96% |
| 2014 Q3 | 21.64 Million USD | -2.04% |
| 2013 FY | 20 Million USD | 222.48% |
| 2013 Q4 | 20 Million USD | 56.55% |
| 2013 Q3 | 12.78 Million USD | 36.35% |
| 2013 Q2 | 9.37 Million USD | 1.09% |
| 2013 Q1 | 9.27 Million USD | 49.45% |
| 2012 Q3 | 7.01 Million USD | -25.94% |
| 2012 FY | 6.2 Million USD | -53.52% |
| 2012 Q4 | 6.2 Million USD | -11.5% |
| 2012 Q1 | 10.44 Million USD | -21.76% |
| 2012 Q2 | 9.46 Million USD | -9.37% |
| 2011 Q2 | 20.46 Million USD | 10.07% |
| 2011 Q3 | 16.66 Million USD | -18.56% |
| 2011 FY | 13.34 Million USD | -7.31% |
| 2011 Q4 | 13.34 Million USD | -19.91% |
| 2011 Q1 | 18.59 Million USD | 29.11% |
| 2010 Q1 | 18.59 Million USD | 81.71% |
| 2010 FY | 14.4 Million USD | 40.74% |
| 2010 Q4 | 14.4 Million USD | -13.0% |
| 2010 Q3 | 16.55 Million USD | -14.59% |
| 2010 Q2 | 19.38 Million USD | 4.23% |
| 2009 Q1 | 9.08 Million USD | -13.64% |
| 2009 FY | 10.23 Million USD | -2.7% |
| 2009 Q4 | 10.23 Million USD | -6.63% |
| 2009 Q3 | 10.95 Million USD | -2.03% |
| 2009 Q2 | 11.18 Million USD | 23.17% |
| 2008 Q2 | 12.86 Million USD | -5.86% |
| 2008 FY | 10.51 Million USD | -33.06% |
| 2008 Q1 | 13.66 Million USD | -13.0% |
| 2008 Q4 | 10.51 Million USD | -14.88% |
| 2008 Q3 | 12.35 Million USD | -3.97% |
| 2007 Q4 | 15.71 Million USD | -2.9% |
| 2007 Q2 | 15.53 Million USD | -5.8% |
| 2007 Q1 | 16.49 Million USD | 1.02% |
| 2007 Q3 | 16.18 Million USD | 4.16% |
| 2007 FY | 15.71 Million USD | -3.76% |
| 2006 Q2 | 15.43 Million USD | -5.17% |
| 2006 Q1 | 16.27 Million USD | -6.04% |
| 2006 FY | 16.32 Million USD | -5.74% |
| 2006 Q4 | 16.32 Million USD | 4.76% |
| 2006 Q3 | 15.58 Million USD | 0.98% |
| 2005 Q3 | 10.81 Million USD | -6.69% |
| 2005 Q4 | 17.31 Million USD | 60.1% |
| 2005 FY | 17.31 Million USD | 54.69% |
| 2005 Q1 | 10.94 Million USD | -2.27% |
| 2005 Q2 | 11.59 Million USD | 5.96% |
| 2004 Q4 | 11.19 Million USD | -0.97% |
| 2004 Q3 | 11.3 Million USD | -41.37% |
| 2004 Q1 | 19.6 Million USD | -1.1% |
| 2004 Q2 | 19.28 Million USD | -1.67% |
| 2004 FY | 11.19 Million USD | -43.53% |
| 2003 FY | 19.82 Million USD | -6.28% |
| 2003 Q4 | 19.82 Million USD | 1.36% |
| 2003 Q3 | 19.56 Million USD | -1.11% |
| 2003 Q2 | 19.78 Million USD | -2.47% |
| 2003 Q1 | 20.28 Million USD | -4.13% |
| 2002 Q1 | - USD | 0.0% |
| 2002 FY | 21.15 Million USD | 0.0% |
| 2002 Q3 | 5401.00 USD | 0.52% |
| 2002 Q2 | 5373.00 USD | 0.0% |
| 2002 Q4 | 21.15 Million USD | 391593.89% |
| 2001 Q1 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -62620.476% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 26.011% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 86.272% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -162.415% |
| Rebus Holdings, Inc. | 5000.00 USD | -28876.86% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 98.887% |
| Qrons Inc. | 420.00 USD | -344862.619% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -88.004% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 94.815% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -201.492% |
| Skye Bioscience, Inc. | 11.94 Million USD | 87.866% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 96.27% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 79.932% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -1797.534% |
| SQZ Biotechnologies Company | 107.18 Million USD | 98.648% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -1.174% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -1902.132% |
| Mesoblast Limited | 667.9 Million USD | 99.783% |
| Marizyme, Inc. | 22.01 Million USD | 93.419% |
| Genus plc | 1.02 Billion USD | 99.859% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -6.662% |
| Pharming Group N.V. | 462.85 Million USD | 99.687% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 56.268% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -190.327% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -131.075% |
| ContraFect Corporation | 20.67 Million USD | 92.994% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -271.15% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -279.103% |
| IMV Inc. | 31.33 Million USD | 95.376% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 65.055% |
| MultiCell Technologies, Inc. | 126.22 USD | -1147771.177% |
| ONE Bio Corp. | 70.08 Million USD | 97.933% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -54.183% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 98.873% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -235.603% |
| Q BioMed Inc. | 3.51 Million USD | 58.787% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 95.882% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -454.524% |
| Biomind Labs Inc. | 73.81 Thousand USD | -1862.697% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.675% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 95.173% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 47.244% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -110.745% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 44.344% |
| GB Sciences, Inc. | 103.44 Thousand USD | -1300.633% |
| Alpha Cognition Inc. | 2.45 Million USD | 40.916% |
| HST Global, Inc. | 1526.00 USD | -94843.84% |
| CSL Limited | 38.02 Billion USD | 99.996% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -46.649% |
| Halberd Corporation | 10.13 Thousand USD | -14201.086% |
| Enzolytics Inc. | 361.7 Million USD | 99.599% |
| Agentix Corp. | 261.39 Thousand USD | -454.28% |
| Resverlogix Corp. | 8.11 Million USD | 82.146% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 22.847% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.968% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 96.963% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -126.503% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -6259.874% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 83.81% |
| AVAX Technologies, Inc. | 7.37 Million USD | 80.36% |
| Zenith Capital Corp. | 7410.00 USD | -19452.537% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.957% |
| Ember Therapeutics, Inc. | 184.00 USD | -787314.674% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -350.222% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -454.339% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -56.132% |
| Kadimastem Ltd | 2.3 Million USD | 37.118% |
| Helix BioMedix, Inc. | 3.02 Million USD | 52.106% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 97.251% |
| BioStem Technologies, Inc. | 14.56 Million USD | 90.049% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -2437.645% |
| LadRx Corporation | 2.3 Million USD | 37.222% |
| Cell Source, Inc. | 195.17 Thousand USD | -642.345% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -309.721% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -309.721% |
| NovAccess Global Inc. | 62.24 Thousand USD | -2227.533% |
| Affymax, Inc. | 7.44 Million USD | 80.534% |
| Itoco Inc. | 1.4 Million USD | -3.483% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -1414.623% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -1266.833% |
| Mobile Lads Corp. | 52.00 USD | -2786136.538% |
| CytoDyn Inc. | 11.13 Million USD | 86.99% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -913.375% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -8003.149% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -275.863% |
| SYBLEU INC | 330.46 Thousand USD | -338.422% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -253.875% |
| International Stem Cell Corporation | 5.39 Million USD | 73.12% |
| Bioxytran, Inc. | 137.63 Thousand USD | -952.648% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 90.342% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 91.261% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -1733.978% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -67.559% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 80.726% |
| Neutra Corp. | 2851.00 USD | -50718.765% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 95.529% |
| PureTech Health plc | 693.97 Million USD | 99.791% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 82.049% |
| IXICO plc | 15.84 Million USD | 90.856% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 82.506% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.598% |
| CSL Limited | 38.02 Billion USD | 99.996% |
| Cellectis S.A. | 333.99 Million USD | 99.566% |